Erickson C. A. et al. (2011)
A prospective open-label study of aripiprazole in fragile X syndrome.
Psychopharmacology (Berl)
July, 216(1), pp. 85-89.
Erickson C. A. et al. (2011)
An open-label naturalistic pilot study of acamprosate in youth with autistic disorder
Journal of Child and Adolescent Psychopharmacology
Erickson C. A. et al. (2010)
Aripiprazole in autism spectrum disorders and fragile X syndrome.
Neurotherapeutics
7(3), pp. 258-263
Erickson C. A. , Mullett J. , McDougle C. J. (2010)
Brief report: acamprosate in fragile X syndrome.
Journal of Autism and Developmental Disorders
40(11), pp. 1412-1416.
Erickson C. A. et al. (2014)
Journal of Autism and Developmental Disorders
April, 44(4), pp. 981-987.
Erickson C. A. et al. (2005)
Gastrointestinal factors in autistic disorder: a critical review.
Journal of Autism and Developmental Disorders
35(6), pp. 713-727
Erickson C. A. , Mullett J. E. , McDougle C. J. (2009)
Open-label memantine in fragile X syndrome.
Journal of Autism and Developmental Disorders
39(12), pp. 1629-1635.
Hazen E. P. et al. (2014)
Sensory symptoms in autism spectrum disorders.
Harvard Review of Psychiatry
22(2), pp. 112-24.
Klaeger D. , McDougle C. J. (2000)
Secretin in autism— a parent’s perspective.
Journal of Autism and Developmental Disorders
30(1), pp. 72-73.
Kowalski J. et al. (2011)
Paliperidone palmitate in a child with autistic disorder.
Journal of Child and Adolescent Psychopharmacology
October, 21(5), pp. 491-493
Lindsay R. L. et al. (2006)
Journal of Intellectual and Developmental Disability
December, 31(4), pp. 204-209.
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
American Journal of Psychiatry
161(6), pp. 1125-1127
McCracken J. T. et al. (2002)
Risperidone in children with autism and serious behavioral problems.
New England Journal of Medicine
347(5), pp. 314-321